Richard A Koup

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses
    Melissa L Precopio
    Immunology Laboratory, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 204:1405-16. 2007
  2. pmc PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
    Constantinos Petrovas
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 203:2281-92. 2006
  3. pmc Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation
    Joseph P Casazza
    Immunology Laboratory, Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD 20892, USA
    J Exp Med 203:2865-77. 2006
  4. pmc Vaccine design for CD8 T lymphocyte responses
    Richard A Koup
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cold Spring Harb Perspect Med 1:a007252. 2011
  5. pmc Standardization of cytokine flow cytometry assays
    Holden T Maecker
    BD Biosciences, San Jose, USA
    BMC Immunol 6:13. 2005
  6. pmc Reconsidering early HIV treatment and supervised treatment interruptions
    Richard A Koup
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS Med 1:e41. 2004
  7. pmc Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials
    Richard A Koup
    Immunology Laboratory, Immunology Core Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 83:6318-22. 2009
  8. pmc Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1650-60. 2006
  9. ncbi request reprint The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration
    Michael R Betts
    Immunology Laboratory, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 172:6407-17. 2004
  10. ncbi request reprint Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Building 40, Bethesda, MD 20892 3017, USA
    Vaccine 25:4085-92. 2007

Detail Information

Publications101 found, 100 shown here

  1. pmc Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses
    Melissa L Precopio
    Immunology Laboratory, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 204:1405-16. 2007
    ..This quality of the CD8(+) T cell response may be at least partially responsible for the profound efficacy of these vaccines in protection against smallpox and serves as a benchmark against which other vaccines can be evaluated...
  2. pmc PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
    Constantinos Petrovas
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 203:2281-92. 2006
    ....
  3. pmc Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation
    Joseph P Casazza
    Immunology Laboratory, Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD 20892, USA
    J Exp Med 203:2865-77. 2006
    ..Thus, mature CMV-specific CD4+ T cells exhibit distinct functional properties reminiscent of antiviral CD8+ T lymphocytes...
  4. pmc Vaccine design for CD8 T lymphocyte responses
    Richard A Koup
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cold Spring Harb Perspect Med 1:a007252. 2011
    ....
  5. pmc Standardization of cytokine flow cytometry assays
    Holden T Maecker
    BD Biosciences, San Jose, USA
    BMC Immunol 6:13. 2005
    ....
  6. pmc Reconsidering early HIV treatment and supervised treatment interruptions
    Richard A Koup
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS Med 1:e41. 2004
  7. pmc Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials
    Richard A Koup
    Immunology Laboratory, Immunology Core Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 83:6318-22. 2009
    ..These data indicate that rAd5-based vaccines containing deletions in the E1, E3, and E4 regions do not induce appreciable expansion of vector-specific CD4(+) T cells...
  8. pmc Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1650-60. 2006
    ..Vaccine Research Center (VRC) 004 is the first phase 1 dose-escalation study of a multiclade HIV-1 DNA vaccine...
  9. ncbi request reprint The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration
    Michael R Betts
    Immunology Laboratory, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 172:6407-17. 2004
    ..The inherent ability of viruses to induce high or low Ag states may be the primary determinant of the cytokine vs cytolytic nature of the virus-specific CD8(+) T cell response...
  10. ncbi request reprint Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Building 40, Bethesda, MD 20892 3017, USA
    Vaccine 25:4085-92. 2007
    ..Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation...
  11. pmc Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
    Richard A Koup
    Vaccine Research Center, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 5:e9015. 2010
    ..Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies...
  12. pmc Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1638-49. 2006
    ..Here, we report the safety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5 (rAd5) vector HIV-1 candidate vaccine...
  13. pmc Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
    Ulrike Wille-Reece
    Cellular Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 203:1249-58. 2006
    ..These data provide insights for designing prime-boost immunization regimens to optimize Th1 and CD8+ T cell responses...
  14. pmc SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection
    Constantinos Petrovas
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Blood 110:928-36. 2007
    ..Manipulation of the interaction of PD-1 with its ligands could thus potentially restore the CD8+ T-cell responses in SIV infection...
  15. pmc T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis
    Jason M Brenchley
    Human Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 78:1160-8. 2004
    ..These data illuminate the underlying mechanisms that distort T-cell homeostasis in HIV infection...
  16. pmc Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection
    Constantinos Petrovas
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA
    J Immunol 183:1120-32. 2009
    ..Thus, our data further support the role of PD-1 as a preapoptotic factor for CD8(+) T cells in HIV infection...
  17. pmc Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses
    David A Price
    Human Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 202:1349-61. 2005
    ..Vaccine strategies that reconstruct these biological processes could generate T cell populations that mediate optimal delivery of antiviral effector function...
  18. pmc Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses
    Karin Lore
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 179:1721-9. 2007
    ..Thus, the ability of rAd35 to naturally target important DC subsets, induce their maturation, and appropriately present Ag to T cells may herald greater in vivo immunogenicity than has been observed with rAd5...
  19. pmc Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inser
    Rebecca L Sheets
    Vaccine Research Center, NIH NIAID, Bethesda, Maryland 20892 7628, USA
    J Immunotoxicol 5:315-35. 2008
    ..These data demonstrate the safety and suitability for investigational human use of Ad5 or Ad35 adenovector-based vaccine candidates at doses of up to 2 x 10(11) given intramuscularly to prevent various infectious diseases...
  20. pmc Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection
    Valentina Cecchinato
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD 20892 5065, USA
    J Immunol 180:5439-47. 2008
    ..These data provide the first direct evidence that immune activation drives viral replication, and suggest caution in the use of therapeutic approaches for HIV infection in vivo that increase CD4(+) T cell proliferation...
  21. pmc Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire
    Joseph P Casazza
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, Maryland 20892, USA
    J Infect Dis 207:1829-40. 2013
    ..The licensing of herpes zoster vaccine has demonstrated that therapeutic vaccination can help control chronic viral infection. Unfortunately, human trials of immunodeficiency virus (HIV) vaccine have shown only marginal efficacy...
  22. pmc High production rates sustain in vivo levels of PD-1high simian immunodeficiency virus-specific CD8 T cells in the face of rapid clearance
    Constantinos Petrovas
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 87:9836-44. 2013
    ..Our data suggest that the persistence of PD-1(high) SIV-specific CD8 T cells in chronic infection is maintained in vivo by a mechanism involving high production coupled with a high disappearance rate. ..
  23. pmc A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, MSC 2610, Bethesda, MD 20892 3017, USA
    Vaccine 26:6338-43. 2008
    ..Over 8000 cases and 900 deaths occurred during the epidemic. We report the safety and immunogenicity of a SARS DNA vaccine in a Phase I human study...
  24. ncbi request reprint Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells
    Jason M Brenchley
    Vaccine Research Center and the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 101:2711-20. 2003
    ..Thus, our studies define a phenotype associated with replicative senescence in HIV-specific CD8(+) T cells, which may have broad implications to other conditions associated with chronic antigenic stimulation...
  25. pmc Amine-reactive dyes for dead cell discrimination in fixed samples
    Stephen P Perfetto
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA
    Curr Protoc Cytom . 2010
    ..This unit describes procedures, troubleshooting, and outcomes for using the two most commonly used amine-reactive dyes, ViViD and Aqua Blue...
  26. pmc Autocrine production of beta-chemokines protects CMV-Specific CD4 T cells from HIV infection
    Joseph P Casazza
    Immunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA
    PLoS Pathog 5:e1000646. 2009
    ..These data suggest that CD4+ T cells which produce MIP-1alpha and MIP-1beta bind these chemokines in an autocrine fashion which decreases the risk of in vivo HIV infection...
  27. pmc Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection
    Christof Geldmacher
    Immunology Laboratory, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 207:2869-81. 2010
    ....
  28. pmc Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection
    Michael R Betts
    Laboratory of Immunology, Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 102:4512-7. 2005
    ..These data suggest that control of HIV by vaccine-elicited HIV-specific T cell responses may be difficult, even when the T cell response has those characteristics predicted to provide optimal protection...
  29. ncbi request reprint HIV preferentially infects HIV-specific CD4+ T cells
    Daniel C Douek
    Vaccine Research Center, NIAID, NIH, Maryland 20892, USA
    Nature 417:95-8. 2002
    ..Furthermore, the phenomenon of HIV specifically infecting the very cells that respond to it adds a cautionary note to the practice of structured therapy interruption...
  30. pmc Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo
    Jason M Brenchley
    Human Virology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA
    J Virol 80:6801-9. 2006
    ....
  31. pmc HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
    Michael R Betts
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 107:4781-9. 2006
    ..Thus, rather than quantity or phenotype, the quality of the CD8(+) T-cell functional response serves as an immune correlate of HIV disease progression and a potential qualifying factor for evaluation of HIV vaccine efficacy...
  32. pmc Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects
    Jorge A Tavel
    Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Acquir Immune Defic Syndr 44:601-5. 2007
    ..To evaluate the safety and immunogenicity of a candidate HIV DNA vaccine administered using a needle-free device...
  33. pmc Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response
    Christof Geldmacher
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA
    Blood 114:1553-62. 2009
    ..Thus, minor viral and host genetic polymorphisms can dramatically alter the immunologic and virologic outcome of an epitope-specific CD8 T-cell response...
  34. ncbi request reprint Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques
    Anna Hryniewicz
    Animal Models and Retroviral Vaccines Section, National Cancer Institute, Building 41, Bethesda, MD 20892, USA
    J Immunol 178:3492-504. 2007
    ..These results underscore the importance of testing immunomodulatory approaches in vivo to assess potential risks and benefits for HIV-1-infected individuals...
  35. pmc Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization
    Cheng Cheng
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892 3005, USA
    J Virol 84:630-8. 2010
    ..These results have implications for future AIDS vaccine trials and the design of next-generation gene-based vaccine vectors...
  36. pmc HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates
    Ulrike Wille-Reece
    Cellular Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 102:15190-4. 2005
    ..This type of vaccine formulation should have utility in preventive or therapeutic vaccines in which humoral and cellular immunity is required...
  37. pmc Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS Med 3:e177. 2006
    ..GP can exert cytopathic effects on transfected cells in vitro, and multiple GP forms have been identified in nature, raising the question of which would be optimal for a human vaccine...
  38. ncbi request reprint Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation
    Michael R Betts
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    J Immunol Methods 281:65-78. 2003
    ....
  39. ncbi request reprint T cell receptor recognition motifs govern immune escape patterns in acute SIV infection
    David A Price
    Human Immunology Section, Vaccine Research Center, NIAID NIH, Bethesda, MD 20892, USA
    Immunity 21:793-803. 2004
    ..These findings have profound implications for the development of vaccines that elicit T cell immunity to combat pathogens with unstable genomes...
  40. ncbi request reprint Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses
    Karin Lore
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3022, USA
    J Immunol 171:4320-8. 2003
    ....
  41. pmc Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity
    Matthew J Johnson
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 188:6109-18. 2012
    ..Taken together, our results demonstrate that rAd-induced IFN-α production has multiple effects on T cell immunogenicity, the understanding of which should be considered in the design of rAd vaccine vectors...
  42. pmc Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection
    Takuya Yamamoto
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA
    J Virol 86:5877-84. 2012
    ..The ability to elicit such virus-specific EM CD8(+) T cells might contribute substantially to an efficacious HIV/AIDS vaccine, even after breakthrough infection...
  43. pmc Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy
    Joseph P Casazza
    Immunology Laboratory, National Institutes of Health, Bethesda, MD 20892, USA
    J Virol 79:3653-63. 2005
    ....
  44. pmc Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals
    Janie Parrino
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 25:1513-25. 2007
    ..MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses...
  45. pmc DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    PLoS ONE 8:e59340. 2013
    ..DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO2-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity...
  46. ncbi request reprint Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry
    Pratip K Chattopadhyay
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, Maryland 20892, USA
    Nat Med 12:972-7. 2006
    ....
  47. ncbi request reprint HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters
    Makoto Sugaya
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, and Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    J Immunol 172:2219-24. 2004
    ..Disrupting cluster formation between LC and memory CD4(+) T cells may be a novel strategy to interfere with sexual transmission of HIV...
  48. pmc Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection
    Takuya Yamamoto
    National Institutes of Health, Bethesda, MD, USA
    Blood 117:4805-15. 2011
    ..Thus, multiple coinhibitory receptors can affect the development of HIV-specific CD8(+) T-cell responses and, by extension, represent potential targets for new immune-based interventions in HIV-infected persons...
  49. doi request reprint CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates
    Nancy J Sullivan
    Vaccine Research Center, US National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 17:1128-31. 2011
    ..Understanding the immunologic mechanism of Ebola virus protection will facilitate the development of vaccines for Ebola and related hemorrhagic fever viruses in humans...
  50. pmc Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques
    Ruth Seggewiss
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Blood 110:441-9. 2007
    ..Thus, our findings suggest that KGF may be a useful adjuvant therapy to augment T-cell reconstitution after human PBPC transplantation...
  51. pmc Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells
    Karin Lore
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 201:2023-33. 2005
    ..This suggests that the induction of antigen-specific T cell responses by DCs, a process crucial to immune defense, can lead to preferential HIV-1 infection and the deletion of responding CD4(+) T cells...
  52. pmc Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
    Mario Roederer
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA
    Nature 505:502-8. 2014
    ..These analyses provide insight into the limited efficacy seen in HIV vaccine trials. ..
  53. pmc CD4 T follicular helper cell dynamics during SIV infection
    Constantinos Petrovas
    Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA
    J Clin Invest 122:3281-94. 2012
    ..Therefore, chronic SIV does not disturb the ability of TFH cells to help B cell maturation and production of SIV-specific immunoglobulins...
  54. pmc Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection
    Christof Geldmacher
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 198:1590-8. 2008
    ..This study was conducted to better understand the mechanism underlying M. tuberculosis-specific pathogenicity early after onset of HIV infection...
  55. pmc Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species
    Lisa E Hensley
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    PLoS Pathog 6:e1000904. 2010
    ....
  56. pmc HIV integration and T cell death: additional commentary
    Arik Cooper
    Virology Laboratory, Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bldg, 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    Retrovirology 10:150. 2013
    ..Nature 498:376-379, 2013). They have raised several hypothetical points that we further clarify here...
  57. ncbi request reprint Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry
    Stephen P Perfetto
    Immunology Laboratory, Vaccine Research Center, NIAID, NIH, 40 Convent Dr, Room 5509, Bethesda, MD 20892, USA
    J Immunol Methods 313:199-208. 2006
    ..Amine reactive viability dyes are a powerful tool for fluorescence immunophenotyping experiments...
  58. pmc Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)
    Mary E Enama
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 9:e91366. 2014
    ..m.) supported proceeding to a Phase 2 b efficacy study. Here we report comparison of the i.m., subcutaneous (s.c.) and intradermal (i.d.) routes of administration...
  59. ncbi request reprint A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape
    Daniel C Douek
    Department of Experimental Transplantation and Immunology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 168:3099-104. 2002
    ..Thus, CD8(+) T cells comprising multiple TCR clonotypes may expand in vivo in response to individual epitopes, and may increase the ability of the response to recognize virus escape mutants...
  60. pmc In vitro culture during retroviral transduction improves thymic repopulation and output after total body irradiation and autologous peripheral blood progenitor cell transplantation in rhesus macaques
    Karin Lore
    Immunology Laboratory, Research Center, National Institute of Allergy and Infectious Diseases, NIH, Department of Health and Human Services, Bethesda, Maryland 20892 1202, USA
    Stem Cells 24:1539-48. 2006
    ..These results have implications for the design of gene therapy trials, as well as for the use of expanded PBPCs for improved T-cell immune reconstitution after transplantation...
  61. pmc A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial
    Julie E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 203:1396-404. 2011
    ..There are no licensed vaccines to prevent WNV in humans. The safety and immunogenicity of a first-generation WNV DNA vaccine was demonstrated in a clinical trial and a similar DNA vaccine has been licensed for use in horses...
  62. pmc Emerging concepts in the immunopathogenesis of AIDS
    Daniel C Douek
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Med 60:471-84. 2009
    ....
  63. pmc A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial
    Julie E Martin
    Vaccine Research Center, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    J Infect Dis 196:1732-40. 2007
    ..West Nile virus (WNV) is a mosquito-borne flavivirus that can cause severe meningitis and encephalitis in infected individuals. We report the safety and immunogenicity of a WNV DNA vaccine in its first phase 1 human study...
  64. ncbi request reprint Viable infectious cell sorting in a BSL-3 facility
    Stephen P Perfetto
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Methods Mol Biol 263:419-24. 2004
    ..With this system in place, aerosol containment can be measured quickly and efficiently, therefore reducing the risk to the operator when sorting viable infectious cells...
  65. pmc A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes, Bethesda, MD 20892 3017, USA
    Clin Vaccine Immunol 13:1267-77. 2006
    ....
  66. ncbi request reprint T cell dynamics in HIV-1 infection
    Daniel C Douek
    Human Immunology Section Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA
    Annu Rev Immunol 21:265-304. 2003
    ....
  67. doi request reprint HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration
    Arik Cooper
    Virology Laboratory, Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    Nature 498:376-9. 2013
    ....
  68. doi request reprint Standard practice for cell sorting in a BSL-3 facility
    Stephen P Perfetto
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Methods Mol Biol 699:449-69. 2011
    ..Subjects covered include containment verification, remote operation, disinfection, personal protective equipment (PPE), and instrument-specific modifications for enhanced aerosol evacuation...
  69. pmc Optimizing peptide matrices for identifying T-cell antigens
    Melissa L Precopio
    Immunology Laboratory, Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cytometry A 73:1071-8. 2008
    ..This optimized deconvolution method allows for efficient mapping of T-cell peptide epitopes. It is rapid, powerful, efficient, and unrestricted by HLA type...
  70. ncbi request reprint Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nature 424:681-4. 2003
    ..This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses...
  71. pmc Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization
    Kylie M Quinn
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 190:2720-35. 2013
    ..Collectively, these data provide the immunologic basis for using specific rAd vectors alone or as part of prime-boost regimens to induce CD8(+) T cells for rapid effector function or robust long-term memory, respectively...
  72. ncbi request reprint IL-7, the thymus, and naïve T cells
    Yukari Okamoto
    Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA
    Adv Exp Med Biol 512:81-90. 2002
  73. ncbi request reprint Detection of T-cell degranulation: CD107a and b
    Michael R Betts
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Methods Cell Biol 75:497-512. 2004
  74. ncbi request reprint Optimal antigens for HIV vaccines based on CD8+ T response, protein length, and sequence variability
    Michael R Betts
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA
    DNA Cell Biol 21:665-70. 2002
    ..The accessory proteins Tat, Rev, Vif, Vpr, and Vpu in general all elicit very low CD8+ T cell responses, and this, in combination with their high variability, makes them less attractive as vaccine antigen...
  75. pmc Heavy metal contaminants can eliminate quantum dot fluorescence
    David Zarkowsky
    Laboratory of Immunology, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland USA
    Cytometry A 79:84-9. 2011
    ..Indeed, these cells can then be successfully stained with other QD reagents, providing a method for immunofluorescence restaining of cells without contaminating fluorescence from the first stain...
  76. doi request reprint The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors
    Richard A Koup
    Richard A Koup, Barney S Graham and Daniel C Douek are at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3017, USA
    Nat Rev Immunol 11:65-70. 2011
    ..Our view is that investing in an iterative approach to human vaccine efficacy trials of sufficient size and sampling frequency will improve the likelihood that an immune correlate of vaccine protection will be defined...
  77. pmc Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies
    Lakshmanan Ganesh
    Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bldg 40, Rm 4502, MSC 3005, 40 Convent Dr, Bethesda, MD 20892 3005, USA
    J Virol 78:11980-7. 2004
    ..This property of DCs may enhance infection, contribute to immune evasion, and could provide a selective advantage for CCR5-tropic virus transmission...
  78. ncbi request reprint Optimized determination of T cell epitope responses
    Mario Roederer
    Vaccine Research Center, NIAID, NIH, 40 Convent Drive, Room 5509, Bethesda, MD 20892, USA
    J Immunol Methods 274:221-8. 2003
    ..In addition, our results guide the design and implementation of the experiments to deconvolute the responses to individual peptide epitopes...
  79. ncbi request reprint Measuring containment of viable infectious cell sorting in high-velocity cell sorters
    Stephen P Perfetto
    Vaccine Research Center, NAID, National Institute of Health, Bethesda, Maryland 20892 3015, USA
    Cytometry A 52:122-30. 2003
    ..With the advent of high-speed sorters, aerosols are a considerable safety concern when sorting viable infectious materials. We describe a four-part safety procedure for validating the containment...
  80. pmc Dynamic bookmarking of primary response genes by p300 and RNA polymerase II complexes
    Jung S Byun
    Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:19286-91. 2009
    ....
  81. ncbi request reprint Effects of exogenous interleukin-7 on human thymus function
    Yukari Okamoto
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases and Department of Experimental Transplantation and Immunology, Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 99:2851-8. 2002
    ..Our results provide compelling evidence that IL-7 has a direct effect on increasing TCR-alphabeta rearrangement and indicate the potential use of IL-7 for enhancing de novo naïve T-cell generation in immunocompromised patients...
  82. ncbi request reprint High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay
    Michael P Crawford
    Department of Pathology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9072, USA
    Blood 103:4222-31. 2004
    ..The results emphasize the need to evaluate both CD4(+) and CD8(+) T-cell responses in MS and to make both subsets a consideration in the development of novel therapeutic strategies...
  83. ncbi request reprint T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment
    Mireya Diaz
    Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio 44106, USA
    AIDS 17:1145-9. 2003
    ..To examine baseline predictors of T-cell receptor rearrangement excision circle (TREC) levels and their changes during treatment with combined antiretroviral therapy...
  84. ncbi request reprint Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia
    Guido Silvestri
    Departments of Medicine and Microbiology and Immunology and, Emory University School of Medicine, Atlanta, GA, USA
    Immunity 18:441-52. 2003
    ..Rather, attenuated immune activation enables SIV-infected mangabeys to avoid the bystander damage seen in pathogenic infections and protects them from developing AIDS...
  85. ncbi request reprint Antiretroviral-drug resistance among patients recently infected with HIV
    Susan J Little
    Antiviral Research Center, Department of Medicine, University of California San Diego, San Diego 92103, USA
    N Engl J Med 347:385-94. 2002
    ..Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estimated at 1 to 11 percent...
  86. pmc Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection
    Melody G Duvall
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom
    J Virol 81:13486-98. 2007
    ....
  87. pmc Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells
    Petra Wolint
    Institute for Microbiology, Eidgenossische Technische Hochschule Zurich, Schmelzbergstrasse 7, 8092, Switzerland
    J Exp Med 199:925-36. 2004
    ..Furthermore, these results provide a potential mechanism by which central memory CD8+ T cell-mediated death of antigen-presenting cells within the lymph node is avoided...
  88. pmc Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations
    Natalie E R Beveridge
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
    Eur J Immunol 37:3089-100. 2007
    ..Overall, these data strongly support the use of MVA85A in humans as a boosting agent to expand polyfunctional M.tb-specific CD4(+) T cells capable of significant secondary responses...
  89. pmc Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen
    Litao Yang
    Department of Immunology, Zhongshan Medical School, Sun Yat Sen University, Guangzhou 510089, China
    J Gen Virol 88:2740-8. 2007
    ..All four immunodominant peptides could elicit cellular immunity with a predominance of CD8+ T-cell response. This data may have important implication for developing SARS vaccines...
  90. pmc Polyfunctional T cell responses are a hallmark of HIV-2 infection
    Melody G Duvall
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Eur J Immunol 38:350-63. 2008
    ..Polyfunctional HIV-specific T cell responses are a hallmark of non-progressive HIV-2 infection and may be related to good clinical outcome in this setting...
  91. ncbi request reprint Human memory T cell responses to SARS-CoV E protein
    Hui Peng
    Department of Immunology, Zhongshan Medical School, Sun Yat Sen University, No 74 ZhongShan Road II, Guangzhou 510089, China
    Microbes Infect 8:2424-31. 2006
    ....
  92. ncbi request reprint Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients
    Li Tao Yang
    Department of Immunology, Zhongshan Medical School, Sun Yat Sen University, 74 Zhongshan 2nd Road, Guangzhou 510080, China
    Clin Immunol 120:171-8. 2006
    ..These data may have an important implication in the possibility of designing effective vaccine against SARS-CoV infection, specifically in defining T-cell populations that are implicated in protective immunity...
  93. ncbi request reprint Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection
    Melody G Duvall
    Medical Research Council MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    J Immunol 176:6973-81. 2006
    ..This study demonstrates that HIV-2-infected donors have a well-preserved and functionally heterogeneous HIV-specific memory CD4+ T cell response that is associated with delayed disease progression in the majority of infected people...
  94. ncbi request reprint Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients
    Hui Peng
    Department of Immunology, Zhongshan Medical School, Sun Yat Sen University, No 74 ZhongShan Road II, Guangzhou 510089, China
    Virology 351:466-75. 2006
    ....
  95. pmc Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells
    Anna Smed-Sorensen
    Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, F59 Huddinge University Hospital, S 141 86 Stockholm, Sweden
    J Virol 79:8861-9. 2005
    ..The difference in susceptibility of PDCs and MDCs to HIV-1 may have implications for HIV-1 transmission and DC-mediated transfer of HIV-1 to T cells...
  96. ncbi request reprint Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells
    Greg M Podsakoff
    Childrens Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA
    Mol Ther 12:77-86. 2005
    ..These findings indicate that there was a selective survival advantage for PBMC containing the huM10 gene during the time of increased HIV-1 load...
  97. pmc Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys
    Michael S Seaman
    Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis, 330 Brookline Ave RE 113, Boston, MA 02215, USA
    J Virol 79:2956-63. 2005
    ..This study demonstrates that it is possible to generate protective immune responses by vaccination with genetically diverse isolates of HIV-1...
  98. ncbi request reprint Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know
    Giuseppe Pantaleo
    Laboratory of AIDS Immunopathogenesis, Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, 1011 Lausanne, Switzerland
    Nat Med 10:806-10. 2004
    ..We will also discuss why it is important to design phase 3 clinical trials of HIV vaccines to determine the correlates of protection for each individual vaccine...
  99. ncbi request reprint Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele
    Guido Ferrari
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 173:2126-33. 2004
    ....
  100. ncbi request reprint Adult human liver contains CD8pos T cells with naive phenotype, but is not a site for conventional alpha beta T cell development
    Lucy Golden-Mason
    Education and Research Center, St Vincent s University Hospital, Dublin, Ireland
    J Immunol 172:5980-5. 2004
    ..The almost complete absence of TRECs suggests that normal AHL is not a site for the development of conventional alphabeta T cells...
  101. pmc Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis
    Nitin J Karandikar
    Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390 9072, USA
    J Clin Invest 109:641-9. 2002
    ....